In 2016, Charles A. Reinhart III joined Pacira as Chief Financial Officer, responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis, and investor relations.
Prior to joining Pacira, Mr. Reinhart served as Chief Financial Officer of Covis Pharmaceuticals, Inc. From September 2011 to August 2014, he served as Executive Vice President and Chief Financial Officer of Archimedes Pharma Ltd. Mr. Reinhart also served as Senior Vice President and Chief Financial Officer of PharmAthene, Inc., a biodefense company engaged in the development of next generation medical countermeasures against biological and chemical threats, from 2009 to 2011. He has also held senior financial roles at Millennium Pharmaceuticals, Inc., Cephalon, Inc. and several early-stage life sciences companies. He also served as a director of Osiris Therapeutics, Inc. (Nasdaq: OSIR) from September 2018 until it was acquired in April 2019. Mr. Reinhart has successfully built and managed finance organizations within rapidly growing companies, responsible for accounting and financial reporting, financial planning and analysis, tax, treasury, risk management and procurement. He has worked closely with commercial teams to evaluate sales operations, monitor product pricing and implement contracting strategies. In addition, he has significant experience in investor relations, corporate development and capital raising. He has been integrally involved in equity and debt financing transactions, as well as the evaluation, acquisition and integration of multiple products and companies.
Mr. Reinhart earned his Bachelor of Science degree from Lehigh University and his MBA from the Wharton School of the University of Pennsylvania. He is also a CPA.
What is Charles A. Reinhart, III's net worth?
The estimated net worth of Charles A. Reinhart, III is at least $839.23 thousand as of June 6th, 2023. Mr. Reinhart, III owns 34,997 shares of Pacira BioSciences stock worth more than $839,228 as of December 4th. This net worth approximation does not reflect any other assets that Mr. Reinhart, III may own. Learn More about Charles A. Reinhart, III's net worth.
How do I contact Charles A. Reinhart, III?
Has Charles A. Reinhart, III been buying or selling shares of Pacira BioSciences?
Charles A. Reinhart, III has not been actively trading shares of Pacira BioSciences within the last three months. Most recently, Charles A. Reinhart III sold 1,236 shares of the business's stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $38.99, for a transaction totalling $48,191.64. Following the completion of the sale, the chief financial officer now directly owns 34,997 shares of the company's stock, valued at $1,364,533.03. Learn More on Charles A. Reinhart, III's trading history.
Who are Pacira BioSciences' active insiders?
Pacira BioSciences' insider roster includes Marcelo Bigal (Director), Mark Froimson (Director), Mark Kronenfeld (Director), Frank Lee (Chief Executive Officer & Director), Donald Manning (Insider), Max Reinhardt (Insider), Charles Reinhart, III (CFO), Lauren Riker (VP), Jonathan Slonin (Chief Medical Officer), David Stack (CEO), Andreas Wicki (Director), Kristen Williams (Insider), Kristen Williams (Chief Administrative Officer & Secretary), and Roy Winston (Insider). Learn More on Pacira BioSciences' active insiders.
Are insiders buying or selling shares of Pacira BioSciences?
In the last twelve months, insiders at the sold shares 6 times. They sold a total of 19,789 shares worth more than $479,312.82. The most recent insider tranaction occured on November, 17th when insider Jonathan Slonin sold 3,960 shares worth more than $95,396.40. Insiders at Pacira BioSciences own 6.4% of the company.
Learn More about insider trades at Pacira BioSciences. Information on this page was last updated on 11/17/2025.
